Studies of HIF activation under normoxic conditions suggest that HIF2α can inhibit FAO, while studies that interfere with HIF2α activation in NAFLD via oxygen therapy or antagonism suggest that HIF2α drives lipogenesis. Here, EPAS1 is linked to metabolic dysfunction-associated steatotic liver disease.